This study provides novel evidence that TZ, an α1-adrenergic receptor antagonist primarily employed in the treatment of BPH and hypertension (65, 66), alleviates age-related endothelial dysfunction by inhibiting MGLL-mediated PA accumulation. Here, MGLL is linked to benign prostatic hyperplasia.